Clinical Trial Update: Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating indium-111 labeled panitumumab for nodal staging in head and neck squamous cell carcinoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 111In-labeled panitumumab (panitumumab)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING